GlaxoSmithKline is not planning to exit the U.K. just because the U.K. is exiting the European Union. As if to emphasize its commitment, the drugmaker said it intends to put a big chunk of money into expanding its manufacturing there.
China's efforts in good manufacturing practice certification in 2015 showed a continued shift toward warning letters even as the overall number of reviewed applications fell by more than half.
Merck & Co. is facing another supply interruption for its ovulation-stimulating hormone Follistim, and like the supply lapse from several years ago, Merck has little to say.
Retailing giant Walmart and global drug wholesaler McKesson would both like to improve their bottom lines and think that pooling their purchasing power for generic meds can help them do that.
